In 2021, 80 ADHD experts from 27 countries selected only large-scale studies to derive 208 evidence-based conclusions. Here are the 5 most important for parents.
- 1) ADHD is a real neurodevelopmental disorder. It is not the result of poor willpower or failed discipline. Collective research has observed brain developmental differences in structure and function.
- 2) Genetic contribution is substantial. Combined twin and adoption studies estimate a considerable genetic contribution at the population level. However, this is not a number that determines any individual's fate.
- 3) Girls are also diagnosed with ADHD. Girls tend to show more inattentive symptoms, meaning diagnosis may be delayed or overlooked.
- 4) Childhood symptoms can persist into adulthood. Not all cases naturally resolve with age, so long-term management may be needed.
- 5) Myths reinforce stigma and delay treatment. Accessing accurate information is the starting point for building your child's management strategy.
In 2023, a large-scale genome-wide association study compared 38,691 individuals with ADHD to 186,843 controls and identified 27 genetic loci associated with ADHD. This strengthens the scientific evidence for a biological basis of ADHD.
"Having a genetic basis" does not mean "genetics determines everything." ADHD results from the accumulation of small contributions from multiple genes, and environmental factors also interact. Even with the same genetic predisposition, symptom expression can vary depending on environment.
"Genetic" is closer to "a starting point for understanding and management" than to "unchangeable."
A 2021 systematic scoping review in JAMA Network Open analyzed 334 studies and identified trends of increasing diagnosis rates and expanding diagnoses in mild cases.
Interpreting this as "overdiagnosis is confirmed" goes beyond this study's conclusions. The researchers did not deny diagnosis itself — they emphasized the importance of following standardized procedures. Increases in diagnoses do not equal "increases in wrong diagnoses" — greater awareness, improved access, and evolving criteria all play a role.
- Ask your specialist whether the evaluation "combined information from multiple settings (home, school)."
- Asking "what criteria and procedures were used" is not questioning the diagnosis — it's understanding the process.
| Item | AAP (US 2019) | NICE NG87 (UK 2018/2019) |
|---|---|---|
| Ages 4–5 First-Line | Behavioral therapy (parent training) | Behavioral therapy (group parent training) |
| Ages 4–5 Medication | Methylphenidate if behavioral therapy insufficient | Second specialist opinion needed under 5 |
| Ages 6+ First-Line | Medication + behavioral therapy | Combined pharmacological + non-pharmacological |
| Ages 6+ Medication Choice | Stimulants (methylphenidate/amphetamine) | Methylphenidate |
| Comorbidities | Separate diagnosis/treatment recommended | Comprehensive treatment plan |
Both guidelines agree that behavioral therapy is the first-line approach for preschoolers (ages 4–5). For school-age children (6+), combined medication and behavioral therapy is recommended first-line.
※ AAP is US-based, NICE is UK-based. These may differ from local healthcare guidelines. This table is meant to illustrate the structure of evidence-based, age-specific recommendations.
These questions can help parents better understand their child's situation during specialist consultations.
- "What criteria and procedures were used for my child's diagnosis?"
→ Understanding the process helps you rationally assess overdiagnosis concerns.
- "What does the guideline recommend as the first-line approach for my child's age?"
→ Knowing that guidelines differ by age makes treatment planning conversations more specific.
- "Can we start with behavioral therapy (parent training) first?"
→ Especially for preschoolers, behavioral therapy is the first-line approach.
- "If ADHD has a genetic basis, should my other children be evaluated?"
→ Research showing substantial genetic contribution can be a starting point for discussing sibling evaluation.
- "How might my child's symptoms change as they grow?"
→ Since some may persist into adulthood, discussing long-term management early is helpful.
※ These questions are not medical advice. They are reference points for conversations with your specialist.
- 📊 Evidence Level: International consensus/guidelines (Grade A), systematic scoping review (Grade B). Even high-grade evidence requires separate consideration for individual application.
- 🧬 Genetics Note: "Substantial genetic contribution" does not mean "genetically determined." Environmental factors also play a role.
- 📋 Guideline Limitations: AAP and NICE are based on US/UK healthcare systems and may differ locally.
- 🎯 Individual Variation: All findings are population-level statistics. Work with your specialist to design "personalized management" for your child.